Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

4D MOLECULAR THERAPEUTICS, INC.

(FDMT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

4D Molecular Therapeutics, Inc.(NasdaqGS:FDMT) added to Russell 3000E Value Index

06/25/2021 | 12:00am EDT

4D Molecular Therapeutics, Inc.(NasdaqGS:FDMT) added to Russell 3000E Value Index


ę S&P Capital IQ 2021
All news about 4D MOLECULAR THERAPEUTICS, INC.
08/124D MOLECULAR THERAPEUTICS : Reports Financial Results for the Second Quarter of 2021 and P..
PU
08/124D MOLECULAR THERAPEUTICS : Management's Discussion and Analysis of Financial Condition an..
AQ
08/124D MOLECULAR THERAPEUTICS INC. : Results of Operations and Financial Condition, Financial ..
AQ
08/124D MOLECULAR THERAPEUTICS : Earnings Flash (FDMT) 4D MOLECULAR THERAPEUTICS Reports Q2 Rev..
MT
08/124D MOLECULAR THERAPEUTICS : Reports Financial Results for the Second Quarter of 2021 and P..
AQ
08/124D Molecular Therapeutics, Inc. Appoints Nadine Greiner as Chief Human Resources Office..
CI
08/124D Molecular Therapeutics, Inc. Announces Unaudited Earnings Results for the Second Qua..
CI
06/254D MOLECULAR THERAPEUTICS INC. : Termination of a Material Definitive Agreement, Other Eve..
AQ
06/254D Molecular Therapeutics, Inc. Announces Rare Disease Ophthalmology Product Candidate ..
CI
06/254D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) added to Russell Microcap Growth Index
CI
More news
Analyst Recommendations on 4D MOLECULAR THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 16,9 M - -
Net income 2021 -71,0 M - -
Net cash 2021 196 M - -
P/E ratio 2021 -13,7x
Yield 2021 -
Capitalization 948 M 948 M -
EV / Sales 2021 44,4x
EV / Sales 2022 280x
Nbr of Employees 104
Free-Float 76,9%
Chart 4D MOLECULAR THERAPEUTICS, INC.
Duration : Period :
4D Molecular Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends 4D MOLECULAR THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 35,12 $
Average target price 50,00 $
Spread / Average Target 42,4%
EPS Revisions
Managers and Directors
David H. Kirn President, Chief Executive Officer & Director
August J. Moretti Chief Financial Officer
John F. Milligan Executive Chairman
Melissa Kotterman Vice President-Discovery & Engineering
Fred Kamal Chief Operating & Technical Officer
Sector and Competitors
1st jan.Capi. (M$)
4D MOLECULAR THERAPEUTICS, INC.-15.27%948
MODERNA, INC.321.86%175 199
LONZA GROUP AG33.09%60 866
IQVIA HOLDINGS INC.44.97%49 103
CELLTRION, INC.-23.26%31 708
SEAGEN INC.-3.41%30 021